Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nancy Kelley, Joachim Schorr

Premium

Nancy Kelley has stepped down from her post as founding executive director of the New York Genome Center. Kelley had been the driving force behind the center's creation and last November had also taken on the role of chief operating officer. As reported by PGx Reporter sister publication In Sequence, Kelley will continue to serve as an advisor and remain on the center's board of directors.


Caris Life Sciences has named Joachim Schorr to be its chief scientific officer.

Schorr formerly worked for two decades at Qiagen, where he was senior vice president of global research and development, managing director, and a member of the executive committee, among other positions. He will continue to serve as a scientific consultant for Qiagen.

Prior to joining Qiagen, Schorr worked at Hoechst, a German chemical-pharmaceuticals company, and was also co-founder of Coley Pharmaceuticals, EnPharma Pharmaceuticals, and QBM Cell Sciences.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.